Has Charishma Nallapati received payments from drug or device companies?

Yes. Drug and device makers reported $43,906 in general payments to Charishma Nallapati across 166 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Charishma Nallapati did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Charishma Nallapati come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Charishma Nallapati

Interventional Cardiology · Houston, TXNPI 1982100236

Payments from drug & device makers

$43,906in general payments, 2019–2025

Across 166 payments — averaging $264.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$29K
Abbott$6K
Edwards Lifesciences$3K
ZOLL Circulation Inc$1K
Amgen$1K
Boston Scientific$903
plus $3K from 18 others

What the payments were for

Grants$28,39265%
Travel & lodging$6,01014%
Food & beverage$8,79820%
Education$7062%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic	11	$29,218
Abbott	43	$5,735
Edwards Lifesciences	18	$2,930
ZOLL Circulation Inc	9	$1,298
Amgen	14	$1,048
Boston Scientific	12	$903
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	12	$697
AstraZeneca	9	$602
Abiomed	4	$329
Novo Nordisk	3	$213
Cardiva Medical, Inc.	6	$163
Boehringer Ingelheim	1	$125
Chiesi USA, Inc.	2	$107
Lantheus Medical Imaging, Inc.	4	$102
Terumo Medical Corporation	3	$74
E.r. Squibb & Sons, L.L.C.	2	$64
Pfizer	3	$58
W. L. Gore & Associates, Inc.	2	$55
Merck	2	$38
Cordis US CORP.	2	$37
Actelion Pharmaceuticals US, Inc.	1	$33
Bridgebio Pharma, Inc.	1	$31
Kiniksa Pharmaceuticals, Ltd.	1	$30
Penumbra, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$43,906 in reported general payments places this provider in the 75th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EntrestoSacubitril/Valsartan	18	$24,423
XareltoRivaroxaban	12	$18,534
Repatha SureclickEvolocumab	17	$9,145
Rosuvastatin Calcium	37	$801
Metoprolol Succinate	35	$644
Atorvastatin Calcium	52	$616
ClopidogrelClopidogrel Bisulfate	32	$368
Losartan Potassium	17	$255
Carvedilol	30	$247
Metoprolol Tartrate	14	$81
Furosemide	12	$21

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Houston

Neal KleimanHouston$4.8M
Juan GranadaHouston$4.3M
Abhijeet DhobleHouston$2.7M
John IsaacHouston$1.8M
Amir KashaniHouston$1.3M
Biswajit KarHouston$785K
Michele SartoriHouston$603K
Guilherme SilvaHouston$516K
Sachin KumarHouston$446K
Marwan JumeanHouston$427K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →